Companies › Renata
1 active drug program in 10 registered trials: 5 Phase 4, 3 Phase 2, 2 Phase 1; Hematology, Oncology, Other.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Eltrombopag Thrombopoietin receptor agonist | MPL | Phase 1 | Primary Immune Thrombocytopenia; Healthy; Hematological Neoplasms; ITP - Immune Thrombocytopenia … | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04600960 | Eltrombopag | Phase 2 | Chemotherapy-induced Thrombocytopenia | Hematology | Mar 2025 |
| NCT06531018 | Eltrombopag | Phase 1 | Primary Immune Thrombocytopenia | Hematology | Aug 2025 |
| NCT06834451 | Eltrombopag | Phase 4 | Healthy | Other | Oct 2025 |
| NCT03844360 | Eltrombopag | Phase 4 | Hematological Neoplasms | Oncology | Dec 2026 |
| NCT07788456 | Eltrombopag | Phase 4 | ITP - Immune Thrombocytopenia | Hematology | May 2027 |
| NCT03206086 | Eltrombopag | Phase 2 | Fanconi Anemia | Hematology | Aug 2028 |
| NCT04518475 | Eltrombopag | Phase 4 | Primary Immune Thrombocytopenia (ITP) | Hematology | Feb 2029 |
| NCT04518475 | Eltrombopag | Phase 4 | Primary Immune Thrombocytopenia (ITP) | Hematology | Feb 2029 |
| NCT01623167 | Eltrombopag | Phase 1 | Severe Aplastic Anemia | Hematology | Nov 2029 |
| NCT04304820 | Eltrombopag | Phase 2 | Severe Aplastic Anemia | Hematology | Dec 2033 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.